Patent application number | Description | Published |
20080213312 | BOTULINUM TOXIN TREATMENTS - A method and composition for treating a patient suffering from a disease, disorder or condition and associated pain include the administration to the patient of a therapeutically effective amount of a neurotoxin selected from a group consisting of Botulinum toxin types A, B, C, D, E, F and G. | 09-04-2008 |
20080213313 | BOTULINUM TOXIN TREATMENTS - A method and composition for treating a patient suffering from a disease, disorder or condition and associated pain include the administration to the patient of a therapeutically effective amount of a neurotoxin selected from a group consisting of Botulinum toxin types A, B, C, D, E, F and G. | 09-04-2008 |
20090123498 | TREATMENT OF POST-STROKE MUSCLE PAIN - A method and composition for treating a patient suffering from a disease, disorder or condition and associated pain include the administration to the patient of a therapeutically effective amount of a neurotoxin selected from a group consisting of Botulinum toxin types A, B, C, D, E, F and G. | 05-14-2009 |
20100121042 | CHIMERA BOTULINUM TOXIN TYPE E - The present invention relates to a toxin comprising a modified light chain of a botulinum toxin type E, wherein the modified light chain comprises amino acid sequence PFVNKQFN (SEQ ID NO: 120) at the N-terminus, and amino acid sequence xExxxLL (SEQ ID NO: 112) at the C-terminus, wherein x is any amino acid. | 05-13-2010 |
20100160609 | Chimera Botulinum Toxin Type E - The present invention relates to a toxin comprising a modified light chain of a botulinum toxin type E, wherein the modified light chain comprises amino acid sequence PFVNKQFN (SEQ ID NO: 120) at the N-terminus, and amino acid sequence xDxxxLL (SEQ ID NO: 111) at the C-terminus, wherein x is any amino acid. | 06-24-2010 |
20100273985 | POST-TRANSLATIONAL MODIFICATIONS AND CLOSTRIDIAL NEUROTOXINS - The present invention discloses modified neurotoxins with altered biological persistence. In one embodiment, the modified neurotoxins are derived from Clostridial botulinum toxins. Such modified neurotoxins may be employed in treating various conditions, including but not limited to muscular disorders, hyperhidrosis, and pain. | 10-28-2010 |
20100273986 | POST-TRANSLATIONAL MODIFICATION AND CLOSTRIDIAL NEUROTOXINS - The present invention discloses modified neurotoxins with altered biological persistence. In one embodiment, the modified neurotoxins are derived from Clostridial botulinum toxins. Such modified neurotoxins may be employed in treating various conditions, including but not limited to muscular disorders, hyperhidrosis, and pain. | 10-28-2010 |
20110046356 | POST-TRANSLATIONAL MODIFICATIONS AND CLOSTRIDIAL NEUROTOXINS - The present invention discloses modified neurotoxins with altered biological persistence. In one embodiment, the modified neurotoxins are derived from Clostridial botulinum toxins. Such modified neurotoxins may be employed in treating various conditions, including but not limited to muscular disorders, hyperhidrosis, and pain. | 02-24-2011 |
20120232022 | BOTULINUM TOXIN TREATMENTS - A method and composition for treating a patient suffering from a disease, disorder or condition and associated pain include the administration to the patient of a therapeutically effective amount of a neurotoxin selected from a group consisting of Botulinum toxin types A, B, C, D, E, F and G. | 09-13-2012 |
20130330369 | Reduction Of Antibody Response Against Botulinum Neurotoxin And Variants Thereof - The present invention provides a method of tolerizing a subject to | 12-12-2013 |